TREATMENT-REFRACTORY CANCERS

Clinical trials for TREATMENT-REFRACTORY CANCERS explained in plain language.

Never miss a new study

Get alerted when new TREATMENT-REFRACTORY CANCERS trials appear

Sign up with your email to follow new studies for TREATMENT-REFRACTORY CANCERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Scientists unleash Triple-Threat immune attack on tough cancers

Disease control Completed

This early-stage study tested a new combination of three immune-boosting drugs (IL-15, nivolumab, and ipilimumab) in adults with advanced cancers that had stopped responding to standard treatments. The main goal was to find the safest dose and understand the side effects of using…

Matched conditions: TREATMENT-REFRACTORY CANCERS

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

TREATMENT-REFRACTORY CANCERS

Get alerted when new TREATMENT-REFRACTORY CANCERS trials appear

Scientists unleash Triple-Threat immune attack on tough cancers